Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity | Zendy

Amy C Sherman | Zendy; Michaël Desjardins | Zendy; ChiAn Cheng | Zendy; Bruce Bausk | Zendy; Natalie E Izaguirre | Zendy; Guohai Zhou | Zendy; Jonathan Krauß | Zendy; Nicole V. Tolan | Zendy; David R. Walt | Zendy; Robert J. Soiffer | Zendy; Vincent T. Ho | Zendy; Nicolas C. Issa | Zendy; Lindsey R. Baden | Zendy

Open Access

Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity

Author(s) -

Amy C Sherman,

Michaël Desjardins,

ChiAn Cheng,

Bruce Bausk,

Natalie E Izaguirre,

Guohai Zhou,

Jonathan Krauß,

Nicole V. Tolan,

David R. Walt,

Robert J. Soiffer,

Vincent T. Ho,

Nicolas C. Issa,

Lindsey R. Baden

Publication year - 2021

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciab930

Subject(s) - reactogenicity , medicine , immunogenicity , hematopoietic stem cell transplantation , immunology , stem cell , haematopoiesis , cohort , coronavirus , virology , antibody , transplantation , covid-19 , biology , disease , genetics , infectious disease (medical specialty)

The severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine–induced humoral response and reactogenicity profile are described in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Findings showed that 75.0% (by Simoa assay) or 80.0% (by Roche assay) of the HSCT cohort had a positive antibody response on series completion, compared with 100% in the healthy cohort.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research